Thus, any drug that may inhibit the production of tumour necrosis factor-alpha, interleukin-1beta, cycloxygenase-2, lipoxygenase, matrix metalloproteinases, or adhesion molecules, or inhibit the activation of NF-kappa B, has the potential to treat arthritis [50]. Here, IL1B is linked to arthritic joint disease.